Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO) filed a Current Report on Form 8-K on March 5, 2026. The filing announces the reporting of financial results for the fiscal year ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the period ended December 31, 2025.
Material Changes
The filing text does not contain specific data regarding material changes in financial performance compared to prior periods. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash position figures for the year ended December 31, 2025.
- Verify year-over-year growth rates and margin trends in the full press release.
- Confirm the company's liquidity position and any updates to debt covenants or financing arrangements.
- Check for any new guidance or operational milestones announced in the press release.